JP2004509869A5 - - Google Patents

Download PDF

Info

Publication number
JP2004509869A5
JP2004509869A5 JP2002529069A JP2002529069A JP2004509869A5 JP 2004509869 A5 JP2004509869 A5 JP 2004509869A5 JP 2002529069 A JP2002529069 A JP 2002529069A JP 2002529069 A JP2002529069 A JP 2002529069A JP 2004509869 A5 JP2004509869 A5 JP 2004509869A5
Authority
JP
Japan
Prior art keywords
compound
group
compound according
diseases
allergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002529069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509869A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/029037 external-priority patent/WO2002024657A2/en
Publication of JP2004509869A publication Critical patent/JP2004509869A/ja
Publication of JP2004509869A5 publication Critical patent/JP2004509869A5/ja
Pending legal-status Critical Current

Links

JP2002529069A 2000-09-20 2001-09-18 二重ヒスタミンh1およびh3アゴニストまたはアンタゴニストとしての、置換されたイミダゾール Pending JP2004509869A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23403800P 2000-09-20 2000-09-20
PCT/US2001/029037 WO2002024657A2 (en) 2000-09-20 2001-09-18 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists

Publications (2)

Publication Number Publication Date
JP2004509869A JP2004509869A (ja) 2004-04-02
JP2004509869A5 true JP2004509869A5 (cg-RX-API-DMAC7.html) 2008-09-11

Family

ID=22879621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002529069A Pending JP2004509869A (ja) 2000-09-20 2001-09-18 二重ヒスタミンh1およびh3アゴニストまたはアンタゴニストとしての、置換されたイミダゾール

Country Status (14)

Country Link
US (1) US6528522B2 (cg-RX-API-DMAC7.html)
EP (1) EP1318993B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004509869A (cg-RX-API-DMAC7.html)
CN (1) CN1558907A (cg-RX-API-DMAC7.html)
AR (1) AR031612A1 (cg-RX-API-DMAC7.html)
AT (1) ATE405557T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001291040A1 (cg-RX-API-DMAC7.html)
CA (1) CA2422210C (cg-RX-API-DMAC7.html)
DE (1) DE60135471D1 (cg-RX-API-DMAC7.html)
ES (1) ES2311544T3 (cg-RX-API-DMAC7.html)
HK (1) HK1052180A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA03002445A (cg-RX-API-DMAC7.html)
MY (1) MY120281A (cg-RX-API-DMAC7.html)
WO (1) WO2002024657A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
RU2015139700A (ru) * 2013-02-19 2017-03-27 Икан Скул Оф Медсин Эт Маунт Синай Трициклические гетероциклические соединения в качестве противораковых средств
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CA2997784A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CN108349943A (zh) 2015-09-09 2018-07-31 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
EP0448765B1 (de) 1990-03-30 1994-08-17 HEUMANN PHARMA GMBH & CO Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
KR940703814A (ko) 1991-12-18 1994-12-12 에릭 에스.딕커 히스타민 H3 작용제/길항제로서의 이미다졸릴-알킬-피페라진 및 -디아제핀 유도체(Imidazolyl-alkyl-piperazine and-diazepine derivatives as histamine H3 agonists/antagonists)
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
ES2188649T3 (es) 1993-11-15 2003-07-01 Schering Corp Fenil-alquil-imidazoles como antagonistas del receptor h3.
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PT1019050E (pt) 1997-06-24 2002-09-30 Novo Nordisk As Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses

Similar Documents

Publication Publication Date Title
CA2257393C (en) Compositions and methods for reducing respiratory depression
JP2007508361A5 (cg-RX-API-DMAC7.html)
JP2006503850A5 (cg-RX-API-DMAC7.html)
JP2008509187A5 (cg-RX-API-DMAC7.html)
JP2006507220A5 (cg-RX-API-DMAC7.html)
JP2003529596A5 (cg-RX-API-DMAC7.html)
JP2002531578A5 (cg-RX-API-DMAC7.html)
JP2005516067A5 (cg-RX-API-DMAC7.html)
JP2005519908A5 (cg-RX-API-DMAC7.html)
JP2009538873A5 (cg-RX-API-DMAC7.html)
SK185399A3 (en) COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION ANDì (54) ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS
JP2005525323A5 (cg-RX-API-DMAC7.html)
JP2005525322A5 (cg-RX-API-DMAC7.html)
RU2002125495A (ru) Гидроксифенил-пиперидин-4-илиден-метил-бензамидные производные для лечения боли
JP2003519228A5 (cg-RX-API-DMAC7.html)
JP2005508872A5 (cg-RX-API-DMAC7.html)
JP2004507527A5 (cg-RX-API-DMAC7.html)
JP2002535370A5 (cg-RX-API-DMAC7.html)
RU2003131970A (ru) Производные 4-(фенил-пиперидин-4-илиден-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств
JP2005538974A5 (cg-RX-API-DMAC7.html)
JP2004504308A5 (cg-RX-API-DMAC7.html)
JP2005532397A5 (cg-RX-API-DMAC7.html)
RU2004139041A (ru) Применение гетероаренкарбоксамидов в качестве дофамин-d3 лигандов для лечения заболеваний центральной нервной системы
JP2003529597A5 (cg-RX-API-DMAC7.html)
JP2006522023A5 (cg-RX-API-DMAC7.html)